Latest Profitability News

SKS Technologies has delivered a remarkable 92% revenue surge in FY25, driven by its data centre strategy and traditional business growth, while expanding bank facilities and forecasting $300 million revenue for FY26.

Scentre Group reported a robust half-year result with profit after tax surging to $782.2 million and Funds From Operations rising 3.2%, underpinned by strong retail sales and near-record occupancy. The Group also advanced a $4 billion development pipeline and sold a 25% stake in Westfield Chermside, maintaining management control.

SKS Technologies Group Limited has reported a remarkable 112% increase in net profit for the financial year ended June 2025, alongside a near doubling of revenue. The company also declared fully franked dividends, signaling confidence in its financial health.

Ingenia Communities Group has reported a robust FY25 performance, exceeding underlying EPS guidance with a 33% increase and signalling strong momentum heading into FY26.

Ingenia Communities Group reported a 9.6% rise in revenue to $517.7 million for FY25, driven by strong home settlements and rental income growth. Underlying profit surged 33% to $126.1 million, while statutory profit soared 816%, reflecting prior year impairments and fair value gains.

Calix Limited reported a $20.1 million loss for FY2025 despite an 11.2% increase in revenue, reflecting ongoing investment in its industrial decarbonisation technology platform.

Kip McGrath Education Centres announces a one-year on-market share buy-back of up to 10% of its shares, aiming to enhance shareholder value amid strong cash reserves and profitability forecasts.

Integral Diagnostics Limited (ASX – IDX) reported a robust FY25 performance, boosted by its transformative merger with Capitol Health Limited. The company posted strong revenue and profit growth, declared a 4.0 cent final dividend, and outlined strategic priorities including AI adoption and teleradiology expansion.

Integrated Research reported steady pro-forma revenue in FY25 despite declines in statutory revenue and profits, driven by a softer renewals book and market uncertainty. The company’s product-led growth strategy gained momentum with new product launches and a major contract renewal.

Integrated Research Limited reported an 18% revenue decline and a 51% drop in net profit for FY25, while unveiling a strategic pivot towards AI-driven product innovation and cloud services.

Imugene Limited reported a significant 54% reduction in net loss for FY25, driven by cost efficiencies and promising clinical progress in its immuno-oncology pipeline. The company’s lead asset, azer-cel, achieved a 79% response rate in Phase 1b trials and secured FDA Fast Track designation.

Mader Group has delivered record FY25 results with revenue climbing 13% to $872.2 million and net profit rising 13%, setting the stage for a $1 billion revenue target in FY26.